BioSpace News Archive

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.

Acorda Therapeutics, Inc. announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg in Spain.

CareDx, Inc. announced the issuance of a new position statement by the American Society of Transplant Surgeons supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.

Novotech, the leading Asia Pacific centred biotech CRO will be at BIO Europe to meet with clinical-stage biotechs and to share the benefits of Novotech’s recently expanded operations in Europe.

POXEL SA, clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced publication in Journal of Hepatology of positive results for DESTINY-1, a 36-week dose-ranging Phase 2 trial.

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 million from new and existing investors.

In the first study to establish patient satisfaction after outpatient total joint arthroplasty in an academic medical center setting, patients indicated they were very likely to undergo the outpatient procedure again and had high patient reported outcomes.

Enthera Pharmaceuticals, a biotech company developing first-in-class biologics for selected autoimmune conditions, announces the start of a Phase 1 first-in-human clinical trial with its lead candidate Ent001.

AlzeCure Pharma AB announced that the company is participating at Redeye Alzheimer Seminar on March 15 at 14:10 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.

iZafe Group (STO:IZAFE-B.ST) iZafe Group (publ.) hereby announces that its wholly owned subsidiary Pilloxa AB is expanding its digital support for patients to Germany in collaboration with Chiesi´s local office.